Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
09 avr. 2024 07h00 HE
|
Nurix Therapeutics, Inc.
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
03 avr. 2024 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
02 avr. 2024 07h00 HE
|
Nurix Therapeutics, Inc.
Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates Nurix will receive a $15.0 million extension fee, and will remain eligible for up...
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
25 mars 2024 07h00 HE
|
Nurix Therapeutics, Inc.
Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer Cancer Grand Challenges is an initiative funded by Cancer Research UK SAN...
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
20 mars 2024 09h40 HE
|
Nurix Therapeutics, Inc.
Disclosure of the discovery and structure of NX-1607, the first inhibitor of CBL-B to advance into clinical studies.
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
11 mars 2024 07h00 HE
|
Nurix Therapeutics, Inc.
Nurix's Phase 1a/1b study of NX-2127 in adults with r/r B-cell malignancies to enroll new patients after partial clinical hold lifted
Nurix Therapeutics to Participate in Upcoming Investor Conferences
06 mars 2024 16h00 HE
|
Nurix Therapeutics, Inc.
Nurix Therapeutics to participate in March investor conferences
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
05 mars 2024 16h30 HE
|
Nurix Therapeutics, Inc.
Nurix to present at AACR2024 Annual Meeting
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
15 févr. 2024 16h00 HE
|
Nurix Therapeutics, Inc.
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
01 févr. 2024 16h01 HE
|
Nurix Therapeutics, Inc.
Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127 NX-2127 degrades BTK in patients regardless of...